Tomoko Nakanishi

Tomoko Nakanishi

Auto-generated profile, based on publicly available information

Tomoko Nakanishi

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
YCYiheng Chen
Yiheng Chen
TLTianyuan Lu
Tianyuan Lu
UPUlrika Pettersson-Kymmer
Ulrika Pettersson-Kymmer
ISIsobel D. Stewart
Isobel D. Stewart
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
JRJ. Brent Richards
J. Brent Richards

25 February 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SZSirui Zhou
Sirui Zhou
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
TNTomoko Nakanishi
Tomoko Nakanishi
DMDavid R. Morrison
David R. Morrison
JAJonathan Afilalo
Jonathan Afilalo
JRJ. Brent Richards
J. Brent Richards

20 February 2023 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
SYSatoshi Yoshiji
Satoshi Yoshiji
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
TLTianyuan Lu
Tianyuan Lu
JWJulian Daniel Sunday Willett
Julian Daniel Sunday Willett
CSChen-Yang Su
Chen-Yang Su
JRJ. Brent Richards
J. Brent Richards

13 January 2022 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JHJennifer E. Huffman
Jennifer E. Huffman
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
AKAtlas Khan
Atlas Khan
EPErola Pairo-Castineira
Erola Pairo-Castineira
TDTheodore G. Drivas
Theodore G. Drivas
HZHugo Zeberg
Hugo Zeberg
The OAS1/2/3 cluster has been identified as a risk locus for severe COVID-19 among individuals of European ancestry, with a protective haplotype of approximately 75 kilobases (kb) derived from Neanderthals in the chromosomal region 12q24.13. This haplotype contains a splice variant of OAS1, which occurs in people of African ancestry independently of gene flow from Neanderthals. Using trans-ancestry fine-mapping approaches in 20,779 hospitalized cases, we demonstrate that this splice variant is likely to be the SNP responsible for the association at this locus, thus strongly implicating OAS1 as an effector gene influencing COVID-19 severity.

1 June 2021 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
TNTomoko Nakanishi
Tomoko Nakanishi
VMVincent Mooser
Vincent Mooser
DMDavid R. Morrison
David R. Morrison
TATala Abdullah
Tala Abdullah
JRJ. Brent Richards
J. Brent Richards
Background: Increased vitamin D levels, as reflected by 25-hydroxy vitamin D (25OHD) measurements, have been proposed to protect against COVID-19 based on in vitro, observational, and ecological studies. However, vitamin D levels are associated with many confounding variables, and thus associations described to date may not be causal. Vitamin D Mendelian randomization (MR) studies have provided results that are concordant with large-scale vitamin D randomized trials. Here, we used 2-sample MR to assess evidence supporting a causal effect of circulating 25OHD levels on COVID-19 susceptibility and severity. Methods and findings: Genetic variants strongly associated with 25OHD levels in a genome-wide association study (GWAS) of 443,734 participants of European ancestry (including 401,460 from the UK Biobank) were used as instrumental variables. GWASs of COVID-19 susceptibility, hospitalization, and severe disease from the COVID-19 Host Genetics Initiative were used as outcome GWASs. These included up to 14,134 individuals with COVID-19, and up to 1,284,876 without COVID-19, from up to 11 countries. SARS-CoV-2 positivity was determined by laboratory testing or medical chart review. Population controls without COVID-19 were also included in the control groups for all outcomes, including hospitalization and severe disease. Analyses were restricted to individuals of European descent when possible. Using inverse-weighted MR, genetically increased 25OHD levels by 1 standard deviation on the logarithmic scale had no significant association with COVID-19 susceptibility (odds ratio [OR] = 0.95; 95% CI 0.84, 1.08; p = 0.44), hospitalization (OR = 1.09; 95% CI: 0.89, 1.33; p = 0.41), and severe disease (OR = 0.97; 95% CI: 0.77, 1.22; p = 0.77). We used an additional 6 meta-analytic methods, as well as conducting sensitivity analyses after removal of variants at risk of horizontal pleiotropy, and obtained similar results. These results may be limited by weak instrument bias in some analyses. Further, our results do not apply to individuals with vitamin D deficiency. Conclusions: In this 2-sample MR study, we did not observe evidence to support an association between 25OHD levels and COVID-19 susceptibility, severity, or hospitalization. Hence, vitamin D supplementation as a means of protecting against worsened COVID-19 outcomes is not supported by genetic evidence. Other therapeutic or preventative avenues should be given higher priority for COVID-19 randomized controlled trials.

1 December 2021 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
TNTomoko Nakanishi
Tomoko Nakanishi
SPSara Pigazzini
Sara Pigazzini
FDFrauke Degenhardt
Frauke Degenhardt
MCMattia Cordioli
Mattia Cordioli
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
AGAndrea Ganna
Andrea Ganna
Background. There is considerable variability in COVID-19 outcomes among younger adults, and some of this variation may be due to genetic predisposition. Methods. We combined individual level data from 13,888 COVID-19 patients (n = 7185 hospitalized) from 17 cohorts in 9 countries to assess the association of the major common COVID-19 genetic risk factor (chromosome 3 locus tagged by rs10490770) with mortality, COVID-19-related complications, and laboratory values. We next performed metaanalyses using FinnGen and the Columbia University COVID-19 Biobank. Results. We found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (HR, 1.4; 95% CI, 1.2–1.7). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (OR, 2.1; 95% CI, 1.6–2.6), venous thromboembolism (OR, 1.7; 95% CI, 1.2–2.4), and hepatic injury (OR, 1.5; 95% CI, 1.2–2.0). Risk allele carriers age 60 years and younger had higher odds of death or severe respiratory failure (OR, 2.7; 95% CI, 1.8–3.9) compared with those of more than 60 years (OR, 1.5; 95% CI, 1.2–1.8; interaction, P = 0.038). Among individuals 60 years and younger who died or experienced severe respiratory failure, 32.3% were risk-variant carriers compared with 13.9% of those not experiencing these outcomes. This risk variant improved the prediction of death or severe respiratory failure similarly to, or better than, most established clinical risk factors. Conclusions. The major common COVID-19 genetic risk factor is associated with increased risks of morbidity and mortality, which are more pronounced among individuals 60 years or younger. The effect was similar in magnitude and more common than most established clinical risk factors, suggesting potential implications for future clinical risk management.